Revival 30mg 30 gastro-resistant capsules — Made in Cyprus — Free Delivery

During treatment, patients should refrain from potentially hazardous activities that require increased attention and speed of psychomotor reactions.

Data on duloxetine overdose are limited. There are reports of taking large doses (up to 1400 mg) of duloxetine alone or in combination with other preparations, which did not have fatal outcomes. Overdose symptoms (mainly when combined with other preparations) included drowsiness, coma, serotonin syndrome, epileptic seizures, vomiting and tachycardia.

Treatment. Specific antidotes are unknown. When serotonin syndrome occurs, specific treatment is necessary (using cyproheptadine and / or temperature control). Airway patency should be checked. Cardiac and vital signs monitoring is recommended, along with appropriate symptomatic and supportive measures. Gastric lavage may be appropriate if performed immediately after taking the preparation. Activated charcoal reduces the absorption of the preparation. Duloxetine has a large volume of distribution in the body, and therefore forced diuresis, hemoperfusion and exchange perfusion are unlikely to be useful.

Dizziness, nausea and headache have been reported as adverse symptoms upon discontinuation of duloxetine. Sensory disturbances, sleep disturbances, agitation or anxiety, tremors, irritability, diarrhea, and hyperhidrosis have also been reported upon discontinuation of duloxetine.

From the endocrine system: hypothyroidism.

From the immune system: anaphylactic reactions, hypersensitivity.

On the part of metabolism: decreased appetite, hyperglycemia, dehydration, hyponatremia, syndrome of inappropriate secretion of antidiuretic hormone.

On the part of the psyche: insomnia, agitation, decreased libido, anxiety, abnormal visions and abnormal orgasm, sleep disorders, bruxism, disorientation, apathy, suicidal thinking, mania, hallucinations, aggression and malice, suicidal behavior.

From the nervous system: headache, drowsiness, dizziness, tremor, paresthesia, myoclonus, akathisia, nervousness, attention disorders, lethargy, dyskinesia, taste disturbances, restless legs syndrome, poor sleep, serotonin syndrome, convulsions, extrapyramidal disorders ..

From the dock of the organs of vision: blurry image, mydriasis, visual disturbances, dry eyes, glaucoma.

On the part of the hearing organs: ringing in the ears, vertigo, pain in the ears.

From the side of the cardiovascular system: palpitations; tachycardia hot flashes; supraventricular arrhythmia; fibrillation, more often atrial; arterial hypertension; increased blood pressure; orthostatic hypotension; loss of consciousness; sensation of coldness in the extremities; hypertensive crisis.

From the respiratory system: yawning, oropharyngeal pain, a feeling of constriction in the throat, epistaxis.

From the digestive tract: nausea, vomiting, dyspepsia, flatulence, abdominal pain, constipation, diarrhea, gastrointestinal bleeding, gastroenteritis, belching, gastritis, stomatitis, bad breath, blood in the stool, dry mouth.

Preparations acting on the central nervous system. When taking duloxetine in combination with other preparations that act on the central nervous system, especially with a similar mechanism of action, including alcohol and sedative preparations, certain precautions must be observed.

MAO inhibitors. Duloxetine should not be co-administered with non-selective irreversible MAO inhibitors due to the risk of serotonin syndrome. When taking reversible selective monoamine oxidase inhibitors (MAOIs), such as moclobemide, the risk of serotonin syndrome is less, but the use of this combination is not recommended.

Medicines containing duloxetine. Co-administration with other medicinal products containing duloxetine should be avoided.

Preparations containing St. John's wort. When used together, adverse reactions often occur.

Store below 25°C in original packaging.

Keep out of the reach of children.

Shelf life - 3 years.